Výsledky vyhledávání - "Johan F.G.A. Jansen"

POS0648 SURVIVAL ANALYSIS OF TIME TO FIRST ADVERSE DRUG REACTION AND DRUG SURVIVAL IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH METHOTREXATE AND HYDROXYCHLOROQUINE MONOTHERAPIES OR COMBINATION THERAPY

Autor: J. Van Lint, K. Velthuis, Naomi T Jessurun, P.M. ten Klooster, Harald E. Vonkeman, M. Nguyen, Johan F.G.A. Jansen, Joep H G Scholl

Publikováno v: Annals of the Rheumatic Diseases. 80:562-563

Background:Methotrexate (MTX) and hydroxychloroquine (HCQ) are first line treatments of rheumatoid arthritis (RA). Adverse drug reactions (ADRs) during treatment with these drugs are common. Survival analysis on time to first ADR and on first time dr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::71019bcd25027c49e7552e17aa212dbb
https://doi.org/10.1136/annrheumdis-2021-eular.181

Zobrazit plný text záznamu

P269 Real-world impact of biological therapies on work impairment and quality of life in Inflammatory Bowel Disease patients

Autor: Rachel West, N. Den Broeder, Johan F.G.A. Jansen, F. Hoentjen, Maurice G. Russel, Pepijn W. A. Thomas, Tessa E H Römkens

Publikováno v: Journal of Crohn's and Colitis. 15:S303-S304

Background Randomised controlled trials have reported improvement of work productivity and activity impairment (WPAI) as well as quality of life in biological-treated inflammatory bowel disease (IBD) patients. However, data beyond clinical trials are

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5995b288d9192cd4d737fce0d6eec5e1
https://doi.org/10.1093/ecco-jcc/jjab076.394

Zobrazit plný text záznamu

P340 Comorbidity is associated with safety outcomes in vedolizumab- and ustekinumab-treated inflammatory bowel disease patients

Autor: Mark Löwenberg, Johan F.G.A. Jansen, Biemans, S van der Marel, J Maljaars, Marie J. Pierik, Rinse K. Weersma, Colitis (Icc), Frank Hoentjen, W van Dop, A Bodelier, N. K. H. de Boer, A. van der Meulen-de Jong, R West, Jeoffrey J L Haans, Asscher, Gerard Dijkstra

Publikováno v: Journal of Crohn's and Colitis. 14:S326-S327

Background The effect of comorbidity on treatment outcomes of vedolizumab and ustekinumab in inflammatory bowel disease (IBD) patients is currently unknown. We aimed to assess the impact of comorbidity on safety and effectiveness of therapy in vedoli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0d14d6959ddebbf42de5b7efcf23fb54
https://doi.org/10.1093/ecco-jcc/jjz203.469

Zobrazit plný text záznamu

DOP51 De-escalation of biological therapy in Inflammatory Bowel Disease patients following prior escalation

Autor: Rachel West, Lisa J T Smits, M Te Groen, Pepijn W. A. Thomas, Tessa E H Römkens, Maurice G. Russel, Johan F.G.A. Jansen, F. Hoentjen

Publikováno v: Journal of Crohn's and Colitis. 15:S086-S086

Background There are limited data available on de-escalation of biological therapy after prior escalation in inflammatory bowel disease (IBD) patients. The aim of this study was to assess the frequency and success rate of de-escalation of biological

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2f4ff516ee0bce358c35dda72644b1de
https://doi.org/10.1093/ecco-jcc/jjab073.090

Zobrazit plný text záznamu

P330 Inflammatory Bowel Disease (IBD) patients frequently report adverse drug reactions during biologic therapy: A multicentre, prospective, patient-reported pharmacovigilance monitoring system

Autor: Rachel West, Frank Hoentjen, Tessa E H Römkens, Maurice G. Russel, J van Lint, Naomi T Jessurun, Johan F.G.A. Jansen, Pepijn W. A. Thomas

Publikováno v: Journal of Crohn's and Colitis. 14:S319-S319

Background The use of biologicals has improved the treatment of IBD but the understanding of adverse drug reactions (ADRs) and the knowledge of patients’ perception on ADRs is poor. Patient-reporting may provide more insight in the extent and burde

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::68b888044e534417847b75afdcd97956
https://doi.org/10.1093/ecco-jcc/jjz203.459

Zobrazit plný text záznamu

SYNTHESIS AND CYTOTOXICITY OF NOVEL LIGNANS

Autor: Niesko Pras, Johan F.G.A. Jansen, O. Middel, W van Uden, Bernard Feringa, A. Van Oeveren, Rm Kellogg, Herman J. Woerdenbag, A.Wt Konings

Publikováno v: Journal of Medicinal Chemistry, 38(12), 2112-2118. AMER CHEMICAL SOC

In this study the syntheses of 11 novel lignans are described. Their cytotoxicities are studied in GLC(4), a human small cell lung carcinoma cell line, using the microculture tetrazolium (MTT) assay. Ten of these compounds were substituted with a men

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66ea80bbb2d69354f361c9996ecc8a00
https://doi.org/10.1021/jm00012a010

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání